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ABSTRACT 
 
Background : Breast cancer is on the first or second most malignancy in many places 
around the world. The incidence of breast cancer was increasing, also in Indonesia. 
Prevention and treatment of breast cancer have not been satisfactory, since patients and 
medical practitioners are searching for other therapeutic and preventive agents. Salvia 
miltiorrhizae Bunge roots is one of the therapeutics agent used in traditional medicine have 
been studied in foreign country. 
Objective : To prove the p53 and Bcl2 expression in C3H mice mammary adenocarcinoma 
using multilevel doses of the Salvia miltiorrhizae Bunge roots extract.  
Methods : The study is a randomized post-test only controlled group design. A total of 18 
adenocarcinoma mice, divided into 3 groups. The first group was administered with 
60mg/KgBW/day and the second group was given by 180mg/KgBW/day, for 21 days. All 
mice were terminated on day 22
nd
. The p53 and Bcl2 expressions were analyzed using 
Allred score, statistically analized by Kruskal Wallis followed by Post-Hoc Mann Whitney 
U test. 
Results : Immunohistochemistry staining shows the p53 expressions have been increased 
between groups, but Bcl2 were decreased. The Kruskal-Wallis and Post-Hoc Mann 
Whitney U test are significantly difference between groups. 
Conclusion : All of the p53 and Bcl2 expressions between groups are significantly 
differences.  
Key words : mammary adenocarcinoma, Salvia miltiorrhizae Bunge, p53, Bcl2 
INTRODUCTION 
In 2012, International Agency for Research on 
Cancer, World Health Organization found that 1,7 
million  womans have been diagnosed with breast 
cancer and there are 6,3 million womans alive that 
have been diagnosed with breast cancer in the 5 
years before. Since 2008, the estimated incidence 
of breast cancer has been increasing by more than 
20%, while the mortality rate has been increasing 
by 14%. Breast cancer is also the most common 
caused of cancer death among womens ( 522.000 
deaths in 2012) and also the most frequently 
diagnosed cancer in womens  in 140 of the 184 
countries all around the world.
 1-3
  
 
 
 
There are no accurate statistical data in 
Indonesia, but the data that have been collected 
from the hospital showed that breast cancer ranked 
first than the other cancer that can be found in 
woman.
 4
  
Breast abnormalities in Indonesian woman 96% 
of it take a form of a tumor are being identified  by  
the patient itself making it easier for the doctor to 
detect breast cancer. Unlike in the western country 
where every childbearing age woman are 
demanded by the Health Insurance company to 
check their breast periodically  so the number of 
early stages breast cancer is much higher than in 
the developing countries where there are no 
necessity for childbearing age woman to check 
their breast..
5,6
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Medical therapy for breast cancer until today 
still didn’t have a satisfactory results.WHO data in 
2008, explained that the people of Asia and Africa, 
80% of them used treatment with plants substance 
so its being called herbal medicine.
7
 Herbal 
medicine that most being used and distributed in 
the world are the Chinese medicine.
 8
 Some of the 
Chinese herbal medicine has been used widely in 
many developing countries, where such therapies is 
acceptable and affordable.
 8
 
One of the many Chinese herbal medicine that 
is widely used is the extract of the dried roots of 
Salvia miltiorrhizzae Bunge, called Danshen. 
Danshen is a plant that is said being a native plants 
from China, but it has been tried to plant this plants 
in other countries, such as Korea, Poland and 
Japan. Danshen that growing outside of China, has 
been studied , have a different content with 
Danshen that growing in the China.
9, 10
 The highest 
content of the active substance is found in  
Danshen that grows in China. Danshen had been 
included in the list of standarized herbal medicine 
in China 
9
,and has been prescribed in many 
countries in the world.
 10
 
Research on the active subtance contained in 
the extract of Salvia miltiorrhizae Bunge in the 
medical world had been done substanstially, with 
the development of knowledge  about the chemical 
composition  of the Salvia miltiorrhizae Bunge has 
been studied and more widely known. 
11,12
 
Composition of the roots extract Salvia 
miltiorrhizae Bunge divided into 2 major part, 
there are the fat-soluble subtance (lipofilik) and the 
water-soluble subtance (hidrofilik). Contents of the 
extract of Salvia miltiorrhizae Bunge are diterpene 
quinon and phenolic acid derivative, including 
tanshinone I, IIA, IIB, cryptotanshinone, 
isocryptotanshinone, miltirone, tanshinol I, II and 
salviol. Those active components that compose the 
extract of Salvia miltiorrhizae Bunge, based on the 
previous studies, it is known that Tanshinone I, 
IIA, IIB, Crypotanshinone, Isocryptotanshinone, 
and various derivative of Tanshinone, compose 
about 5% of 100mg Salvia miltiorrhizae Bunge 
extract.
9-12
 
Previous experimental study, used  20mg/Kg 
BW Tanshinone i.v., in this study  will be proposed 
dose of 60mg/Kg BW per day orally, and 
180mg/Kg BW per day orally, which take a part on 
the role of malignant cell apopthosis pathway.
13
 
One of the content  of Danshen  have a protective 
effect against lipid peroxidation in vitro and in 
vivo. 11 Tanshinone and its derivatives are 
components of Salvia miltiorrhizae Bunge extract 
that plays an active role in the mechanism of 
carsinogenesis, which has been proved through 
previous  experimental studies both in vitro and in 
vivo.
12
  
In the pharmacopoeia of the Chinese said that 
the recommended dosage is 9-15 grams per daily 
dose in the form of boiled medicine. In some case, 
a high dose was given, up to 20 grams per day, in 
the case of an inflamatorry diseases including viral 
hepatitis. According to Materia Medica Cina 
Langka, doses up to 30-60 grams can be used in 
cases of angina and athritis. Relatively high dose of 
Salvia, compared to other Chinese herbs (typical 
dosage recommendation is 3-9 grams for many 
herbs) may be associated with  relatively low levels 
of active constituents and low solubility in water. 
13
 
At higher dose, salvia can caused dry mouth, 
dizziness, fatigue, numbness, shortness of breath, 
and other symptoms that will usually dissapear 
spontaneously without interupting treatment. 
Materia Medica Cina Langka noted that salvia 
isn’t suitable for patients who have blood 
deficiency accompanied with cold, or with a 
tendency of bleeding. However, most of the guide 
in  materia medica  didn’t warned this. Salvia has a 
very low acute toxicity, with LD50 injection of 40-
80 g/Kg BW.
13
 
Suggestion of using salvia are for poor blood 
circulation treatment, it can’t be combined with 
coumadin (warfarin), because there is a possibility 
of  increased anticoagulant effect. In a literature 
survey conducted in October 2000,  Dalam sebuah 
survei literatur dilakukan melalui Oktober 2000,  it 
have been found three cases of increasing 
anticoagulant activity.In the literature, people take 
Salvia along with Warfarin. Such effect may be 
rare and tend to be dose dependent, as the 
mechanism  appears to be a simple addictive effect 
of the anticoagulant activity of Salvia along with 
that being produced by Warfarin. Therefore, people 
who use Coumadin should either avoid using 
Salvia, or use it  in a relatively  low dose ( no more 
than equivalent of 6-9 gram per day in the boiled 
dose) with attention to the routine blood clotting 
tests for those who taking the drug.
 13
 
Toxic doses of the Salvia miltiorrhizae Bunge 
root extract hasn’t widely known. Oral dose given 
to mice  for 90 days  at 400 times of the 
recommended  human doses (2.500 mg/Kg BW), 
was reported to be toxic. Lethal dose of the Salvia 
miltiorrhiza Bunge extract that soluble in the water 
are being reported 25g/Kg BW in mice.
12
  
Salvia miltiorrhizae Bunge root extract is 
known to have an effect that primarily related with 
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cardiovasculer, angina pectoris, cerebrovascular, 
antiplatelet, anticoagulant and thrombolytic , 
antibiotic, hepatoprotective, and CNS suppresant/ 
sedative effect.
 11
 Data from United States Patent 
Application Publication, stated that 
pharmacological activity of  Salvia miltiorrhizae 
Bunge, as mentioned above, as well as anti-
neoplastic or anti-cancer.
13 
Experimental studies 
have been conducted on the anti-cancer mechanism  
of Tanshinone as one of the active ingredients  of 
Danshen, on human breast cancer.
 13,14
 
Cytotoxic effects, anti-neoplastic of the active 
subtance of  Salvia miltiorrhizae Bunge  root 
extract has been  studied previously, in the 
malingnant cells of the colon, ovary, lung, mouth, 
breast, and leukemia.
 13-17
 
Breast cancer study as an example, the results 
showed  that Tanshinone have a stronger inhibitory 
effect than Tamoxifen, which Tanshinone 
effectively induce apoptosis in breast cancer cell  
which had positive and negative estrogen 
receptor.
13,14
 In this study use only one of the  
active subtances  contained in the Salvia 
miltiorrhizae Bunge root extract. 12 Previous 
research states that more complex  form of the 
herbal preparations would have a better effect than 
just the active substance, therefore in this research 
is very interesting is to study Salvia miltiorrhizae 
Bunge root extract in the raw form, without 
purification. 
18,19
 
A statement  that Tanshinone  from Salvia 
miltiorrhizae Bunge root extract has a stronger 
effect  on breast cancer than  tamoxifen  as an 
standart hormonal anti-neoplastic agent, it is 
necessary  to know more about the effect of Salvia 
miltiorrhizae Bunge root extract,  that is the 
complex compound form  in the living system of 
the carsinoma mammae cell up to apoptosis 
stage.
13,14,18,19
 
Carcinogenesis process involves 4 things, 
which is: 1. Oncogene, 2. Tumor Suppresor Gene, 
3. DNA Mismatch-Repair Genes, 4. Apoptosis.
20 
1. Oncogene 
Proliferation in normal cells is controlled by 
proteins  in cell membrane, which will affect the 
cascade  of biochemical signals , a signal 
transduction process. Those proteins are growth 
factor and cytokines (protein mediation). The 
signals control genes that regulate  cell growth and 
division. Oncogene is converted into normal 
cellular genes called proto-oncogene which is 
involved  in this cascade events. Proto-oncogene 
mutations predicted spontaneously,  through 
interaction  with  virus, or  by chemical or physical 
agents. When proto-oncogene converted to 
oncogene, cellgrowth and proliferation pathways 
changed. This can cause the abnormal cells growth 
( neoplastic transformation). More than 100 
oncogenes  has been identified. Genes are the 
medium by which  a cell produce proteism, that 
each  of it has a very spesific role. A mutated  gene 
can caused to over production of a protein, or 
lower production of a protein, or a change in the 
protein that may not be able to carry out its 
objectives. Onkogene usually produce more certain 
proteins when mutated, while tumor suppressor 
gene normally produce less proteins product that is 
needed  to suppress the growth when mutated
20
 
2. Tumor Suppressor Gene 
Activation of oncogene and inactivation of 
tumor suppressor gene is needed  in the process of 
cancer . Tumor suppressor gene normally 
associated with cell growth and differentiation and 
programed cell death (apoptosis).  More than 12 
tumor suppressor genes have been identified. 
Proteins produced  by  tumor suppressor genes  
normally  inhibit proliferating cells or splitting 
during  the period when growth and not when the 
DNA repairing occured. Tumor suppressor gene is 
like a “brake” of a cell. Mutation that inactive 
tumor suppressor gene as an example is the p53 
gene mutation, which is the most common 
mutation  seen in human cancer, found about 50%. 
Breast carcinoma, colon, abdomen, urinary bladder 
and testicle, melanoma, and soft tissue sarcoma  all 
associated  with the mutations in the p53 gene. P53 
protein is found in the nucleus  of cell and regulate 
cell functions  such as cell growth, DNA repair, 
and apoptosis. The most important role of p53 is to 
stop the growth of a cell , allowing the cell to have 
time to repair the damaged DNA. If the p53 gene 
mutated, then the p53 gene loss the function to 
repaired damaged DNA,  then apoptosis doesn’t 
occured, and the results is unregulated cell growth.
 
20
 
3. DNA Mismatch-Repair Genes 
Dna Mismatch-Repair Genes found to be 
associated with cancer susceptibility and genetic 
instability of cancer cells that allows multiple 
mutations to occured. This instability accelerated 
the progress of the cancer. The normal functions of 
this gene is to repair damaged DNA. Mutations in 
the DNA mismatch-repair genes most important is 
in the hereditary non-polyposis colorectal cancer 
(HNPCC). 
20
 
4. Apoptosis 
Apoptosis is programmed cell death, or cell 
suicide program , this programs refers to to the 
4 
 
Journal of Biomedicine and Translational Research 02(2016) 1 - 9 
death of the damage cell. It is not random, but 
occurs in cells with damaged DNA. When cell 
mutated and can’t repair itself, then that cell can be 
sacrificed to prevent worse mutation that are 
inherited to the next generation of cells. Inhibition 
of apoptosis might be an important step in 
carcinogenesis.  2 genes involved in the apoptosis 
are tumor suppressor gene p53 and Bcl2 proto-
oncogene.
20 
Research problems emerge after knowing the 
role of p53 and Bcl2 both cellular and molecular. 
Are there differences in the expression of p53 and 
Bcl2 in breast adenocarcinoma in C3H mices that 
have been given Salvia miltiorrhizae Bunge root 
extract compared the group who weren’t given  
Salvia miltiorrhizae Bunge root extract? This study 
aims to prove increase expression of p53 and 
decrease expression of Bcl2 in the breast 
adenocarcinoma of C3H mices that have been 
given multilevel doses of  Salvia miltiorrhizae 
Bunge root extract. This study is expected to 
provide concrete evidence, increasing knowledge 
and can be applied practically in the medical 
practice, that there is drugs besides synthetic 
chemical based drugs including  phytopharmaca or 
herbal  drugs that also can be used for breast 
cancer treatment or as a combination. The results 
of this study are expected to provide a role in the 
development of medical science in the future so 
that it can show the benefit of phytopharmaca or 
herbal medicine, also it can be base for future 
research , and complement prior knowledge, so it 
will obtain more complete and right knowledge 
about herbal medicine to a disease. For the 
community, the results of this study expected  add 
knowledge for general public, about the use of 
phytopharmaca.  
 
METHOD  
Laboratory experimental research with 
randomized  post test only controlled group design 
on 18 and 1 C3H mice that have induced breast 
adenocarcinoma which were obtained from the 
Laboratory of Experimental Pathology , University 
of Indonesia in Jakarta, with the inclusion criteria : 
C3H female mice that have tumor and appeared to 
be healthy and active, aged 6-8 weeks ,with body 
weight between 20-30 grams and no anatomical 
abnormalities, while the drop out criteria is when 
the mice died during treatment. Tumor C3H mice  
were then divided into 3 groups, controls , 
treatment 1 (were given Salvia miltiorrhizae Bunge 
extract 60mg/Kg BW/day dissolved in water, then 
given per soner) and  treatment 2 (180mg/Kg 
BW/day), for 21 days. One tumor C3H mice was 
terminated at day 1 of the study to determine the 
type of the tumor breast adenocarcinoma.  
Before the experiments started the mice has 
been weighed with weight scale and mass 
measured using calliper, as well as 21 days after 
treatment. On the 22th day, all mice were 
terminated using ether chloride, then the growing 
tumor mass being excised. The tumor mass 
preparation the being fixated with 10% buffered 
formalin and being processed with routine 
histopathology tissue, paraffin blocks were made 
then thinly slices using a microtome for each block 
as 3 slides. One slide is attached to normal object 
glass then given routine staining using 
hematoxyllin eosin (HE). Other slides attached to 
object glass that contains poly-L-lysine layer 
(PolysineTM Microslides; MENZEL-GLASER) 
then being process for immunohistochemical 
staining for p53 and Bcl2 proteins. Evaluation of 
p53 and Bcl2 expression used Allred score 67 and 
read by 2 anatomical pathologist.  
Data that has been collected are primary data 
results of the scoring of p53 and Bcl2 expression 
based on Allred score and  dan processed with 
computer program SPSS 15.0 for Windows. 
Statistical analysis were being performed with 
significance difference between 2 groups, using 
Mann-Whitney test and  Kruskal-Wallis test was 
used to test differences more than 2 groups. P 
values was considered significant if p ≤ 0,05 with a 
95% degree of confidence and 80% power. 
 
RESULTS 
Up to 21th day, there are no mice that fall into 
drop out criteria. Interpretation of p53 and Bcl2 
expression using Allred score,  perfomed by 2 
experts in Anatomical Pathology with Kappa test 
results that showed a correlation coefficient close 
to 1, specifically 0,704 for p53 expression and 
0,832 for Bcl2 expression with significancy of 
0,000 which means that 2 assessors mutually 
consistent   
Mean descriptive analysis of p53 expression 
showed the highest result were in the 3rd group, 
the group of tumor C3H mices that was given 
180mg/Kg BW/day Salvia miltiorrhizae Bunge 
root extract. Mean of the lowest p53 expression 
was showed by the 1st group, the group of tumor 
C3H mices that wasn’t given Salvia miltiorrhizae 
bunge root extract. 
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Table 1. Mean Differences of p53 expression using  
Allred score  
Group N Mean Median 
Standart 
Deviation 
Kruskal 
Wallis 
Df p 
C 30 3,3667 3,0000 0,66868 2 0,000 
T1 30 3,8333 4,0000 0,74664  
T2 30 4,8000 5,0000 1,03057  
Uji Kruskal Wallis p=0,000 (p≤0,05), significant 
 
Mann Whitney test was performed to determine 
significant differences between treatment group , 
and the results is significant in all comparisons 
between. 
Table 2. Expression of p53 Difference test between 
treatments groups 
 
 
 
 
 
While the mean descriptive analysis of Bcl2 
expression showed the lowest results were in the 
3rd group the group of tumor C3H mices that was 
given 180mg/Kg BW/day Salvia miltiorrhizae 
Bunge root extract. Mean of the highest Bcl2 
expression was showed by the 1st group, the group 
of tumor C3H mices that wasn’t given Salvia 
miltiorrhizae bunge root extract. 
 
Table 3. Mean Differences of Bcl2 expression using  Allred 
score 
Groups N Mean Median 
Standart 
Deviation 
Kruskal 
Wallis 
Df p 
C 30 6,3000 6,0000 0,46609 2 0,000 
T1 30 5,3333 6,0000 0,80230  
T2 30 4,4667 4,0000 0,97320  
Uji Kruskal Wallis p=0,000 (p≤0,05), significant 
Mann Whitney test was performed to determine 
significant differences between treatment group , 
and the results is significant in all comparisons 
between. 
 
Microscopic Description 
 
 
 
 
 
 
 
 
 
 
Figure 1. First day termination,  
 
Hematoxyllin Eosin (HE) staining, 400x. Cells 
appeared to be round, ovale, hard pleiomorfik, 
rough chromatine (red arrow), mitotic appearance 
± 20/10 HPF, partially in groups, forming 
glandular structures ± 20%, invaded swollen 
stroma fibromixoid connective tissue surrounded 
by lymphocytes histiocytes inflammatory cells, and 
invasion of the blood vessels, and necrotic 
appearance in the center. The description above 
was suitable with Breast adenocarcinoma in C3H 
Mice. 
 
Hematoxyllin Eosin Staining, 400x 
magnification 
 
 
 
Figure 2. A. Control Group; B. Treatment Group 1; 
C.Treatment Group 2 
 
 
 
 
 
 
 
Group I Group J Z (I-J) P 
Control  Treatment 1 -2,711 0,007 
Control  Treatment 2 -5,017 0,000 
Treatment 1 Treatment 2 -3,604 0,000 
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p53 Imunohistochemical  staining, 400x 
magnification 
 
 
 
Figure 3.  p53 expression showed with the brown color in 
the nucleus of the breast adenocarcinoma cells .  
A.Control Group , Allred score 3; B.Treatment Group 1, 
Allred score 4; C.Treatment Group 2, Allred score 5 
 
 
 
 
 
 
 
 
 
 
Figure 4. Bcl2 expression showed with the brown color in 
the cytoplasm and nucleus membrane of the breast 
adenocarcinoma cells. 
 A.Control Group, Allred score 5; B. Treatment Group 1, 
Allred score 4; C.Treatment Group 2, Allred score 2 
 
DISCUSSION 
Breast carcinoma is a malignancy that ranked 
1st or 2nd in many places around the world, with 
an increasing incidence, as well as in Indonesia. 
Preventive and curative measure hasn’t been 
satisfying. Herbal medicine used by eastern 
medicine, like Salvia miltiorrhizae Bunge root 
extract that contain active subtance tanshinone and 
its derivatives, which has been previously studied 
abroad and are known to have anti carcinogenic 
effects. Until now it has been known many 
path/pathways of carcinogenesis, including Tumor 
Suppresor Gene inactivation or activation of proto 
oncogene. P53 is a protein with an important role 
as a protector of the genes, so it was called “ the 
guardian of the genome”, “guardiang angel gene”, 
or “master watchman”. In the apoptotic pathway, 
p53 transcribes a large number of proteins that 
involved intrinsic and extrinsic  apoptosis 
pathways, it plays an important role in protecting 
cells from genetic mutations because of damaged 
DNA.  
P53 expression has many varieties, its depends 
on the variety of conditions and cellular functions, 
regulation, apoptosis, DNA replication, 
proliferation, etc. In the normal conditions, 
concentration amount of p53 (p53 null) in the 
cytoplasm are very low and only activated when 
cells experienced stress, where this p53 null will 
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transform to p53 wild, which will protect cells 
from many genetic mutations into p53 mutant. In 
malignancy conditions, p53 wild concentration are 
decreasing because of the genetic mutations, so 
that previous journal said that wild p53 protein can 
be one of the prognostic factor,  in the incidence of 
malignancy. 
In this study the results were consistent with the 
previous studies,  that in the control group, it was 
found that p53 expression was significantly lower  
than treatment group 2. 
 Bcl2 protein has an important  function as key 
regulator of the mitochondrial apoptotic pathway. 
These proteins control  mitochondrial outer 
membrane (MOM) permeability which release 
cytochrome c and other apoptotic factor into 
cytosol. This leads to activation of the caspase 
cascade  that considered  as the point of no return 
in programmed cell death. Apoptotic regulation by 
the Bcl2 protein is essential for the tissue 
homeostasis, embryonic development and 
maturation of blood cells.
 48
 One important thing, 
the deregulation  of Bcl2 protein has a major role 
in the formation of tumors and in the cellular 
response to anticancer therapy. Bcl2 family are 
also involved in other diseases, such as 
autoimmune, infectious, and neurodegenerative 
disorders.  On the other hand, there is increasing 
evidence that Bcl2 family proteins also have other 
additional function in the celullar processes, such 
as in the mitochondria and metabolism, which 
remain mostly yet unknown.
 49
 Over the last 25 
years, Bcl2 family proteins widely studied because 
of the biological relevance and potential as 
theurapetic target. 20 or more members  of the 
Blc2 family proteins have been identified and 
classified  according to its function in apoptosis.  
The result of this study showed that the 
expression of Bcl2 in the group that has been given 
Salvia miltiorrhizae Bunge root extract seem 
significantly lower than the group which weren’t 
given the treatment. The findings of this studies 
indicate that, Salvia miltiorrhizae Bunge root 
extract give a function to fix anti apoptotic 
condition,  which is expected to become a new 
hope both for breast cancer patient and clinicians. 
The weakness of this study are, the dose used 
for the calculations was using the base dose for the 
cardiovascular problems, and there has been no 
definite dose for malignancy, so further researchs 
is needed to determine the appropriate doses for 
malignancy conditions which possible to be 
different with the dose for cardiovascular 
problems. It also makes Salvia miltiorrhizae Bunge 
root extract dose has yet to be applied to humans, 
so its suggested also for futher research in human 
dose adjusment.   
 
CONCLUSIONS 
From the results of the study, it can be 
concludes  that there is meaningful difference in  
the increased expression of p53 and decrease 
expression of Bcl2 of the breast adenorcarcinoma 
in the C3H mices that were given multilevel doses 
of  Salvia miltiorrhizae Bunge root extract. 
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